B2BROKER
26.10.2021 09:02:17 CEST | Business Wire | Press release
B2Broker, a leading technology and liquidity provider in the Forex and Crypto industry, has announced the introduction of a series of outstanding new conditions for its Margin and Crypto Spot liquidity offerings. With today’s announcement comes a new pricing structure that delivers an ultra competitive proposition which is unmatchable in the industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211026005100/en/
B2Broker launched its initial Crypto CFD offering back in 2017, starting with 30 Crypto CFD pairs. The company was the first in this space to implement a Prime Broker business model approach in the Crypto CFD offering. Today, it offers a total of 115 Crypto pairs making it the industry’s leading Crypto CFD provider as well as a tier 1 liquidity provider in the Spot FX, Metals, Equity Indices, Commodities, Single Stocks, and ETFs space all from a single margin account.
To date, B2Broker is used by more than 50% of FX Retail Brokers/Props Houses/Funds, etc, who offer Crypto CFDs and require a main liquidity provider or secondary source of liquidity.
Margin Liquidity
As the popularity of margin trading continues to reach new heights, the new trading conditions from B2Broker will enable its clients to benefit from a whole range of new features and advantages. These include:
New Crypto CFDs
We have added a further 15 new crypto CFDs to our liquidity pool that have proved highly popular recently:
XRP, Cardano, Dogecoin, Solana, Polkadot, Chainlink, Polygon, Uniswap, HIBA INU, Algorand, Avalanche, Terra, Filecoin, Vechain and Maker.
Note: all trade against the USD.
New Margin Requirements
New margin requirements on major crypto CFDs have been decreased from 20% to 10% . This will allow greater opportunities for traders around the world to leverage our unbeatable conditions.
The list of symbols that we have applied changes to include:
BTC/USD, BCH/USD, ETH/USD, LTC/USD, XRP/USD
BTC/EUR, BCH/EUR, ETH/EUR, LTC/EUR, XRP/EUR
BTC/GBP, BCH/GBP, ETH/GBP, LTC/GBP
New Pricing Policy
New commercial offers have been introduced to serve all types of business models. Whether you need a white label solution, a FIX API/gateway connection or an enterprise solution, B2Broker offers a bespoke proposition that serves your business according to your requirements.
Our new Enterprise offering includes PrimeXM or OneZero HUB along with a liquidity solution that gives brokers greater flexibility in terms of managing their liquidity price streams and risk management solutions. The main idea behind this package is to offer broker dealers a solution where they will be able to use our liquidity along with leading HUBs/XCOREs in a more efficient and cost-effective way. For example, if you go directly to PrimeXM or OneZero and buy a Hub with them and then approach B2Broker to buy liquidity, it will prove to be more expensive than simply buying a single Enterprise pack from B2Broker.
The Enterprise liquidity solution is ideal for Brokers who have their own Trading Server such as MT5, MT4, C-Trader etc, and want to be able to manage their price streams, markups, swaps, risk management and more.
New Liquidity Pool Locations
Our liquidity pools are now based in main locations around the world such as LD4, NY4, TY3, SG1 and Mainland China (Beijing). You can choose the best suitable location for your API/Gateway connection.
For our WL clients based in LD4, we have created a global network of access servers which provide the lowest latency connection from any point in the world.
Liquidity Distribution
We offer liquidity distribution across the following platforms to cater for the broad-based demands of our clients PrimeXM, OneZero, FixAPI, MT5, MT4 for FX/CFD, Crypto CFDs etc and B2Trader, Rest API and WEBSocket for Crypto Spot liquidity.
Crypto Spot Liquidity
On the Crypto Spot liquidity side of things, we have introduced a range of outstanding new developments which are applicable to B2BX:
A. Revised ultra-competitive commission ladder which goes down to 0.04%.
B. In total we have enhanced the depth of order book to 100 levels per each side (Buy and Sell) to satisfy the requirements of major players. The compressed order book contains over 120 BTC with an average spread of just $7 USD and market impact of around $140 USD.
C. Increased our trading pairs to consist of additional stable coins and all the top tokens.
B2Broker CEO, Arthur Azizov commented, “We constantly seek to improve our offers and are positioned to offer an unbeatable pricing structure for our services, as well as other favourable conditions which will ultimately benefit our clients. Our liquidity services can be accessed quickly and easily with the most advantageous prices available within the industry and the highest level of technical support”.
B2Broker’s liquidity solutions are used by various types of financial institutions who benefit from our expertise and technology, and our ability to deliver customised liquidity solutions tailored to our clients exact needs. B2Broker offers liquidity on Spot FX, Metals, Commodities, Single Stocks with over 400 instruments, working as a PoP, rather than a market maker. We are therefore on the broker’s side at all times, enabling the best possible liquidity provision in keeping with our clients’ interests.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005100/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom